Amarin Corporation PLC (AMRN)vsMerck & Company Inc (MRK)
AMRN
Amarin Corporation PLC
$14.68
+1.45%
HEALTHCARE · Cap: $301.45M
MRK
Merck & Company Inc
$119.37
+2.58%
HEALTHCARE · Cap: $287.71B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 30329% more annual revenue ($65.01B vs $213.65M). MRK leads profitability with a 28.1% profit margin vs -18.2%. AMRN appears more attractively valued with a PEG of 0.81. MRK earns a higher WallStSmart Score of 59/100 (C).
AMRN
Hold39
out of 100
Grade: F
MRK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AMRN.
Margin of Safety
-141.2%
Fair Value
$49.50
Current Price
$119.37
$69.87 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Growing faster than its price suggests
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
ROE of -8.2% — below average capital efficiency
Revenue declined 21.0%
Earnings declined 94.2%
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : AMRN
The strongest argument for AMRN centers on Price/Book, Debt/Equity, PEG Ratio. PEG of 0.81 suggests the stock is reasonably priced for its growth.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bear Case : AMRN
The primary concerns for AMRN are Market Cap, Return on Equity, Revenue Growth.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
AMRN profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.
AMRN carries more volatility with a beta of 0.89 — expect wider price swings.
MRK is growing revenue faster at 5.0% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 39/100), backed by strong 28.1% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amarin Corporation PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Amarin Corporation plc, a pharmaceutical company, is engaged in the development and commercialization of therapies for the treatment of cardiovascular disease in the United States. The company is headquartered in Dublin, Ireland.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?